Liposomes Industry to 2034 - Recent Development
The global liposomes
market is anticipated to reach a size of US$ 7.87 Bn in 2025. It is
predicted to rise at a CAGR of 6% during the forecast period to reach a value
of US$ 11.83 Bn by 2032.
Liposome manufacturing is gaining importance in the
biopharmaceutical industry to tackle drug development challenges like poor solubility
and low permeability of active pharmaceutical ingredients (APIs). Liposomes,
tiny vesicles with lipid bilayers, provide targeted drug delivery, enhancing
treatment effectiveness and minimizing side effects. Consequently, making them
valuable in therapeutic areas like cancer, genetic disorders, and infectious
diseases.
Recent Development
• In June
2022, Endo Ventures Limited (EVL), a subsidiary of Endo International plc,
acquired the clinical-stage private pharmaceutical company Taiwan Liposome Co.,
Ltd. signed an agreement with (TLC) will market TLC's research product, TLC599.
TLC599 is an injectable drug in development stage 3 for the treatment of
osteoarthritic knee pain.
• In January
2022, Pfizer and Acuitas Therapeutics signed a development and options
agreement in which Pfizer will have the option to license Acuitas' lipid
nanoparticle (LNP) technology for use of up to 10 Enhancements of the vaccine.
or treatment.
• In June
2018, Virpax ฤฐlaรง A.ล. partnered with LipoCure to manufacture liposomes and
develop pain management products.

Comments
Post a Comment